Niels Christoph Riedemann

This inventor holds 12 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 5 EPO patents. Top assignee: Inflarx Gmbh. Active years: 2014-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Niels Christoph Riedemann. Retrieved from https://idiyas.com/inventor/niels-christoph-riedemann

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 12 (Patent Applications = 2)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 4)

EPO Patents = 5 (Patent Applications = 11)

Average Co-Inventor Count = 2.4

ph-index = 4

Forward Citations = 47(Granted Patents)

Location History:

Jeny, DE (2019 - 2020)
Jena, DE (2014 - 2024)

Company Filing History:

12 out of 14

Inflarx Gmbh

patents

Years Active: 2014-2026

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12697351 - METHOD OF TREATING CONDITIONS, REDUCING AN INFLAMMATORY RESPONSE, OR IMPROVING ORGAN FUNCTION IN A SUBJECT HAVING A CORONA VIRUS INFECTION BY ADMINISTERING AN INHIBITOR OF C5A ACTIVITY (2026-08-04),

2. 12180274 - Treatment of pneumonia and ARDS with inhibitors of C5a and IL-6 activity (2024-12-31),

3. 11999698 - Fused piperidinyl bicyclic and related compounds as modulators of C5a receptor (2024-06-04),

4. 11890349 - Treatment of inflammatory diseases with inhibitors of C5A activity (2024-02-06),

5. 11464868 - Treatment of inflammatory diseases with inhibitors of C5A activity (2022-10-11),

6. 11149009 - Fused piperidinyl bicyclic and related compounds as modulators of C5A receptor (2021-10-19),

7. 10858421 - Inhibitors of C5A for the treatment of viral pneumonia (2020-12-08),

8. 10774136 - Anti-C5a binding moieties with high blocking activity (2020-09-15),

9. 10376595 - Treatment of inflammatory diseases with inhibitors of C5a activity (2019-08-13),

10. 10227397 - Inhibitors of C5a for the treatment of viral pneumonia (2019-03-12),

11. 9458233 - Anti-C5a binding moieties with high blocking activity (2016-10-04),

12. 8802096 - Anti-C5a binding antibodies with high block activity (2014-08-12),

Title: Innovations and Contributions of Niels Christoph Riedemann

Introduction

Niels Christoph Riedemann, an accomplished inventor based in Jena, Germany, has made significant strides in the field of medical research and pharmacology. With a portfolio of 10 patents, he has been instrumental in developing innovative treatments that address critical health challenges.

Latest Patents

Among his latest patents, Riedemann has developed a groundbreaking method for the treatment of pneumonia and acute respiratory distress syndrome (ARDS) using inhibitors of C5a and IL-6 activity. This invention focuses on the effectiveness of these inhibitors in combating infectious pneumonia and ARDS, offering new hope for patients suffering from these severe respiratory conditions.

Another notable patent from Riedemann involves fused piperidinyl bicyclic and related compounds, which serve as modulators of the C5a receptor. This invention explores the binding capabilities of these compounds to C5a receptors and their applications in pharmaceutical compositions intended for treating diseases linked to the pathogenic activation of these receptors.

Career Highlights

Currently, Riedemann is associated with Inflarx GmbH, a company dedicated to developing innovative therapies for autoimmune and inflammatory diseases. His work at Inflarx showcases his commitment to advancing medical solutions that enhance patient care and outcomes.

Collaborations

Throughout his career, Riedemann has collaborated with notable colleagues such as Renfeng Guo and Yan Li. These partnerships have fostered a creative environment that encourages the fusion of ideas and expertise, further driving innovation in their projects.

Conclusion

Niels Christoph Riedemann stands out as a remarkable inventor whose contributions to medical science have the potential to save lives and improve health standards. Through his diligent work and collaborations, he continues to pave the way for innovative therapies that address significant health issues. His advancements not only reflect his expertise but also his dedication to enhancing the quality of life through scientific innovation.

Profile summary based on public USPTO records.